What questions do holders want asked at the AGM?, page-2

re GvHD

Q2. Will management verify there is a high probability of recruiting 60 patients in a timely manner from specific centers (or centres) and countries prior to formerly committing to a phase 2 GvHD trial?

re Manufacturing and partnering

Q3. Will management advise if Fujifilm is ready, or how close it is to being ready, to manufacture cells for partners if partners were available?

Q4. Will management confirm that should they wish to prospective partners could still choose to use another manufacturer rather that Fujifilm, and so Fujifilm manufacturing would be an option for potential partners not an obligation?

Q5. Can management offer prospective partners a path toward 3D commercial scale manufacturing if partners were interested or do partners have to investigate potential IP arrangements and impediments or the lack of such with third parties themselves?

R and D

Q6. Has management considered prototyping 3D manufacturing using CYP MSCs at a small scale like in say a 5Litre bioreactor so as to be able to offer a proof of concept? Perhaps arranging with a university or engineering group to do the prototyping - then verifying the 2D and 3D manufactured cells are the same - and also establishing that micro carriers can be added and removed without problems for the cells?